Literature DB >> 12435811

Mutation of Asn293 to Asp in transmembrane helix VI abolishes agonist-induced but not constitutive activity of the beta(2)-adrenergic receptor.

Annette Hannawacker1, Cornelius Krasel, Martin J Lohse.   

Abstract

The beta(2)-adrenergic receptor has been shown to display significant constitutive activity (i.e., in the absence of agonist) in addition to agonist-induced activation. Various studies have suggested that a movement in transmembrane helix VI plays a role in activation of various G-protein-coupled receptors. Here we show that a mutation in this domain of the beta(2)-adrenergic receptor abolishes agonist activation but not constitutive activity. An Asn293Asp mutant of the human beta(2)-adrenergic receptor was expressed either transiently in COS-7 cells or stably in Chinese hamster ovary cells. The mutant receptors were unable to couple to G(s), as seen by the lack of high-affinity agonist binding as well as a reduction of the affinities of several agonists correlating with their intrinsic activities. The mutant receptors caused only minimal activation of adenylyl cyclase (2.5% of wild-type activity) and also failed to show agonist-induced phosphorylation by G-protein-coupled receptor kinase 2. In contrast, the mutant receptors were much less affected in their constitutive activity: transient transfection of wild-type and mutant receptors into COS-7 cells caused an increase in intracellular cAMP-levels that was dependent on the level of receptor expression and was maximally 5.4-fold for the mutant and 6.8-fold for the wild-type receptors (67% of wild-type activity). Introduction of the Asn293Asp mutation into a constitutively active mutant receptor did not affect the constitutive activity of this mutant. These results underscore the importance of transmembrane helix VI in controlling agonist-induced activation of the receptor and suggest that constitutive activity is different from agonist-induced activity. Furthermore, they indicate that Asn293 is a key residue in transferring conformational information from the agonist-binding site to the intracellular surface.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435811     DOI: 10.1124/mol.62.6.1431

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

Review 1.  The β2-adrenergic receptor-ROS signaling axis: An overlooked component of β2AR function?

Authors:  Kalyn M Rambacher; Nader H Moniri
Journal:  Biochem Pharmacol       Date:  2019-11-05       Impact factor: 5.858

2.  Understanding the effects on constitutive activation and drug binding of a D130N mutation in the β2 adrenergic receptor via molecular dynamics simulation.

Authors:  Yanyan Zhu; Yuan Yuan; Xiuchan Xiao; Liyun Zhang; Yanzhi Guo; Xuemei Pu
Journal:  J Mol Model       Date:  2014-10-25       Impact factor: 1.810

3.  GPCR agonist binding revealed by modeling and crystallography.

Authors:  Vsevolod Katritch; Ruben Abagyan
Journal:  Trends Pharmacol Sci       Date:  2011-09-06       Impact factor: 14.819

4.  Docking studies on a refined human beta(2) adrenoceptor model yield theoretical affinity values in function with experimental values for R-ligands, but not for S-antagonists.

Authors:  Marvin A Soriano-Ursúa; José G Trujillo-Ferrara; Jesús Alvarez-Cedillo; José Correa-Basurto
Journal:  J Mol Model       Date:  2009-07-22       Impact factor: 1.810

5.  Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.

Authors:  Vsevolod Katritch; Kimberly A Reynolds; Vadim Cherezov; Michael A Hanson; Christopher B Roth; Mark Yeager; Ruben Abagyan
Journal:  J Mol Recognit       Date:  2009 Jul-Aug       Impact factor: 2.137

6.  Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation.

Authors:  Supriyo Bhattacharya; Spencer E Hall; Hubert Li; Nagarajan Vaidehi
Journal:  Biophys J       Date:  2007-12-07       Impact factor: 4.033

7.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor.

Authors:  Michael A Hanson; Vadim Cherezov; Mark T Griffith; Christopher B Roth; Veli-Pekka Jaakola; Ellen Y T Chien; Jeffrey Velasquez; Peter Kuhn; Raymond C Stevens
Journal:  Structure       Date:  2008-06       Impact factor: 5.006

8.  Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-mediated cAMP signaling.

Authors:  Peter T Wright; Viacheslav O Nikolaev; Thomas O'Hara; Ivan Diakonov; Anamika Bhargava; Sergiy Tokar; Sophie Schobesberger; Andrew I Shevchuk; Markus B Sikkel; Ross Wilkinson; Natalia A Trayanova; Alexander R Lyon; Sian E Harding; Julia Gorelik
Journal:  J Mol Cell Cardiol       Date:  2013-12-15       Impact factor: 5.000

9.  A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor.

Authors:  Gill Holdsworth; Daniel A Osborne; TrucChi Thi Pham; James I Fells; Gillian Hutchinson; Graeme Milligan; Abby L Parrill
Journal:  BMC Biochem       Date:  2004-08-06       Impact factor: 4.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.